India’s scientific community watched with growing excitement as news emerged from the American Heart Association’s Scientific Sessions 2025. At a global conference where world-leading breakthroughs are unveiled, early results from a small 15-patient trial captured extraordinary attention. For the first time, a one-time CRISPR-Cas9 gene-editing therapy had shown the potential to dramatically and safely lower both LDL cholesterol and triglycerides two stubborn drivers of heart disease. The therapy, called CTX310, works like a microscopic courier.
Using tiny fat-based particles, it travels to the liver carrying the CRISPR mechanism. Its mission is precise: switch off the ANGPTL3 gene, a natural regulator of blood fats. Scientists have long known that people born with this gene turned off have lifelong low cholesterol and triglycerides. Now, for the first time, researchers attempted to…
